Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. (AORT) reported insider share transactions by its Chief Commercial Officer on Form 4. On November 14, 2025 and November 17, 2025, the officer exercised stock options to acquire 6,393 and 6,394 shares of common stock, respectively, at an exercise price of $29.62 per share. On the same dates, the officer sold the same numbers of shares at prices of $44.67 and $45.17 per share. After these transactions, the officer directly owned 198,842 shares of Artivion common stock. The filing notes that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options originally began vesting on March 5, 2020.
Artivion, Inc. (AORT) reported an insider stock sale by a senior officer. On 11/17/2025, the company’s VP and Chief Accounting Officer sold 6,000 shares of common stock in an open market transaction at a weighted average price of $45.73 per share, with trade prices ranging from $45.605 to $45.91. After this transaction, the officer beneficially owns 135,380 shares of Artivion common stock, held directly. The filing notes that detailed price breakdowns for each trade within the reported range are available upon request.
AORT filed a Form 144 indicating an intended sale of restricted or control securities. The filing covers a planned sale of 6,394 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $288,816.98. These shares are part of a class with 47,374,939 shares outstanding, and the approximate sale date is 11/17/2025 on the NYSE.
The seller acquired these shares on 11/17/2025 through an option granted on 03/05/2019, paid in cash. Over the prior three months, John E. Davis reported additional sales of common shares: 3,373 shares on 11/10/2025 for $150,499.55, 6,563 shares on 11/13/2025 for $300,968.02, and 6,393 shares on 11/14/2025 for $285,575.31.
AORT received a Form 144 notice indicating that Amy D. Horton plans to sell 6,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 11/17/2025. The filing notes that there were 47,374,939 common shares outstanding at the time referenced in the form.
The shares to be sold were originally acquired via restricted stock vesting from the issuer as compensation in February 2017, in two grants of 3,491 and 2,509 shares. Over the past three months, the seller has already sold 1,789 and 3,482 common shares, generating gross proceeds of $79,823.21 and $159,678.60, respectively.
Artivion, Inc. (AORT)6,394 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $288,816.98. These shares were acquired on 11/17/2025 through the cash exercise of an employee stock option originally granted on 03/05/2019. The filing notes that 47,374,939 common shares were outstanding. Over the prior three months, the same seller, Jean F. Holloway, reported selling additional common shares in three transactions totaling 22,154 shares for gross proceeds of $1,013,674.66.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 2,020,000 shares of Artivion, Inc. (AORT) common stock, representing 4.3% of the class. The percentage is based on 47,374,939 shares outstanding as of October 31, 2025, as disclosed by the company.
The filers report shared voting power and shared dispositive power over 2,020,000 shares, with no sole voting or dispositive power. They certify the holdings were not acquired to change or influence control of Artivion.
AORT filed a Form 144 notice for a proposed sale of up to 6,393 shares of common stock with an aggregate market value of $287,685.00. The filing lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 11/14/2025, and the NYSE as the exchange.
The seller previously completed several sales in the past three months: 10,000 shares on 11/11/2025 for $461,800.00, 5,761 shares on 11/13/2025 for $264,189.66, and 2,960 shares on 11/10/2025 for $132,071.94. Shares outstanding were 47,374,939.
Artivion (AORT) disclosed an insider transaction by its VP, Chief Accounting Officer. On 11/13/2025, the officer sold 3,482 shares of common stock at $45.858 per share. According to the filing, the sale was executed to cover tax withholding triggered by the vesting of restricted stock units and “does not represent a discretionary transaction.”
Following this sell-to-cover transaction, the officer beneficially owned 141,380 shares, held directly.
Artivion, Inc. (AORT) reported an insider Form 4. The Chief Commercial Officer sold 6,563 shares of common stock at $45.858 on 11/13/2025 (Transaction code: S). According to the footnote, the shares were sold upon RSU vesting to cover tax withholding via a “sell to cover” and do not represent a discretionary transaction.
After the sale, the reporting person beneficially owned 198,842 shares, held directly.
Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.
Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.